Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure

BACKGROUND: There is currently insufficient information available on effective therapies that can be administered to patients with non‐small cell cancer (NSCLC) who develop resistance to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). However, sequential treatment via progra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaira, Kyoichi, Kobayashi, Kunihiko, Shiono, Ayako, Yamaguchi, Ou, Hashimoto, Kosuke, Mouri, Atsuto, Shinomiya, Shun, Miura, Yu, Imai, Hisao, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952801/
https://www.ncbi.nlm.nih.gov/pubmed/33522139
http://dx.doi.org/10.1111/1759-7714.13864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952801/
https://www.ncbi.nlm.nih.gov/pubmed/33522139
http://dx.doi.org/10.1111/1759-7714.13864

Ejemplares similares